Medchemexpress LLC VIT-2763 | 2095668-10-1 | 99.9% | 408.43 | 50 MG

Supplier:  Medchemexpress LLC HY11222050MG

VIT-2763 is an oral ferroportin inhibitor designed to inhibit hepcidin binding to ferroportin and block iron efflux. It holds potential for treating β-thalassemia by addressing iron regulation. This compound has demonstrated significant biological activity both in vitro and in vivo.

• Reduces fluorescence polarization signal by displacing TMR-hepcidin from ferroportin.
• Induces BLA reporter gene activity, increasing intracellular iron concentrations by blocking iron export.
• Triggers ubiquitination and degradation of ferroportin.
• Corrects anemia and improves red blood cell parameters in relevant animal models.
• Decreases the percentage of ROS-positive red blood cells and extends their lifespan.
• Significantly decreases serum iron levels in animal studies.
• Currently undergoing Phase 2 clinical trials for Beta-Thalassemia and Sickle Cell Disease.

Catalog No. 50-004-37853